BIOMAT Database Logo BIOMAT Database Logo

Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis. 2006

K Psathakis, and D Mermigkis, and G Papatheodorou, and S Loukides, and P Panagou, and V Polychronopoulos, and N M Siafakas, and D Bouros
Department of Pneumonology and the Clinical Research Unit, Army General Hospital of Athens, and Department of Pneumonology, University Hospital of Heraklion, Greece. kpsazakis@hol.gr

BACKGROUND Expired breath condensate (EBC) has never been used to explore the level of oxidative stress in idiopathic pulmonary fibrosis (IPF). Therefore, the aim of this study was to measure the levels of H2O2 and 8-isoprostane, as biomarkers of oxidative stress, in the EBC of patients with IPF. METHODS We investigated 16 patients with IPF and 15 healthy subjects as the control group. The levels of H2O2 and 8-isoprostane were measured in the EBC of all subjects and were compared between the IPF and control groups. In patients with IPF, H2O2 and 8-isoprostane were further correlated with pulmonary function tests (PFTs), the resting pO2 and the differential cell count from the bronchoalveolar lavage fluid (BALF). RESULTS The mean (95%CI) concentration of H2O2 was increased in the patients with IPF compared with the normal subjects (0.36, 0.24-0.47 microM vs. 0.16, 0.10-0.23 microM, P=0.003). The mean (95%CI) concentration of 8-isoprostane was also increased in the patients with IPF compared with the controls (74, 38-110 pg mL-1 vs. 33, 28-39 pg mL-1, P=0.02). In the patients with IPF, the diffusing capacity of the lung for carbon monoxide was negatively correlated with the levels of H2O2 in EBC (P=0.03, r=-0.58). No other correlation was found between the oxidative stress markers in the EBC and PFT values, pO2 or BALF cell count. CONCLUSIONS Our data suggest that H2O2 and 8-isoprostane are increased in the EBC of patients with IPF. H2O2 may be correlated with the severity of the disease in IPF.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011658 Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death. Alveolitis, Fibrosing,Idiopathic Diffuse Interstitial Pulmonary Fibrosis,Fibroses, Pulmonary,Fibrosis, Pulmonary,Pulmonary Fibroses,Alveolitides, Fibrosing,Fibrosing Alveolitides,Fibrosing Alveolitis
D012129 Respiratory Function Tests Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc. Lung Function Tests,Pulmonary Function Tests,Function Test, Pulmonary,Function Tests, Pulmonary,Pulmonary Function Test,Test, Pulmonary Function,Tests, Pulmonary Function,Function Test, Lung,Function Test, Respiratory,Function Tests, Lung,Function Tests, Respiratory,Lung Function Test,Respiratory Function Test,Test, Lung Function,Test, Respiratory Function,Tests, Lung Function,Tests, Respiratory Function
D001944 Breath Tests Any tests done on exhaled air. Breathalyzer Tests,Breath Test,Breathalyzer Test,Test, Breath,Test, Breathalyzer,Tests, Breath,Tests, Breathalyzer
D001992 Bronchoalveolar Lavage Fluid Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung. Alveolar Lavage Fluid,Bronchial Lavage Fluid,Lung Lavage Fluid,Bronchial Alveolar Lavage Fluid,Lavage Fluid, Bronchial,Lavage Fluid, Lung,Pulmonary Lavage Fluid,Alveolar Lavage Fluids,Bronchial Lavage Fluids,Bronchoalveolar Lavage Fluids,Lavage Fluid, Alveolar,Lavage Fluid, Bronchoalveolar,Lavage Fluid, Pulmonary,Lavage Fluids, Alveolar,Lavage Fluids, Bronchial,Lavage Fluids, Bronchoalveolar,Lavage Fluids, Lung,Lavage Fluids, Pulmonary,Lung Lavage Fluids,Pulmonary Lavage Fluids
D002452 Cell Count The number of CELLS of a specific kind, usually measured per unit volume or area of sample. Cell Density,Cell Number,Cell Counts,Cell Densities,Cell Numbers,Count, Cell,Counts, Cell,Densities, Cell,Density, Cell,Number, Cell,Numbers, Cell
D005260 Female Females
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Psathakis, and D Mermigkis, and G Papatheodorou, and S Loukides, and P Panagou, and V Polychronopoulos, and N M Siafakas, and D Bouros
Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis.
July 1999, Free radical biology & medicine,
K Psathakis, and D Mermigkis, and G Papatheodorou, and S Loukides, and P Panagou, and V Polychronopoulos, and N M Siafakas, and D Bouros
Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis.
September 2010, Free radical biology & medicine,
K Psathakis, and D Mermigkis, and G Papatheodorou, and S Loukides, and P Panagou, and V Polychronopoulos, and N M Siafakas, and D Bouros
[Idiopathic pulmonary fibrosis: serum markers].
June 2005, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
K Psathakis, and D Mermigkis, and G Papatheodorou, and S Loukides, and P Panagou, and V Polychronopoulos, and N M Siafakas, and D Bouros
ROCK activation in lung of idiopathic pulmonary fibrosis with oxidative stress.
January 2014, International journal of immunopathology and pharmacology,
K Psathakis, and D Mermigkis, and G Papatheodorou, and S Loukides, and P Panagou, and V Polychronopoulos, and N M Siafakas, and D Bouros
Oxidative Stress in Pulmonary Fibrosis.
March 2020, Comprehensive Physiology,
K Psathakis, and D Mermigkis, and G Papatheodorou, and S Loukides, and P Panagou, and V Polychronopoulos, and N M Siafakas, and D Bouros
Elevated levels of oxidative stress markers in exhaled breath condensate.
February 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
K Psathakis, and D Mermigkis, and G Papatheodorou, and S Loukides, and P Panagou, and V Polychronopoulos, and N M Siafakas, and D Bouros
Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis.
January 2021, Frontiers in pharmacology,
K Psathakis, and D Mermigkis, and G Papatheodorou, and S Loukides, and P Panagou, and V Polychronopoulos, and N M Siafakas, and D Bouros
Oxidative stress and inflammation parameters-novel biomarkers for idiopathic pulmonary fibrosis.
February 2022, European review for medical and pharmacological sciences,
K Psathakis, and D Mermigkis, and G Papatheodorou, and S Loukides, and P Panagou, and V Polychronopoulos, and N M Siafakas, and D Bouros
Unraveling the interplay between vital organelle stress and oxidative stress in idiopathic pulmonary fibrosis.
March 2024, Biochimica et biophysica acta. Molecular cell research,
K Psathakis, and D Mermigkis, and G Papatheodorou, and S Loukides, and P Panagou, and V Polychronopoulos, and N M Siafakas, and D Bouros
Exhaled markers of antioxidant activity and oxidative stress in stable cystic fibrosis patients with moderate lung disease.
February 2018, Journal of breath research,
Copied contents to your clipboard!